Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance...

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1993 May 1

PMID 8517697

Citations 109

Authors

A J Japour

D L Mayers

V A Johnson

D R Kuritzkes

L A Beckett

J M Arduino

J Lane

R J Black

P S Reichelderfer

R T DAquila

Affiliations

Soon will be listed here.

Abstract

A standardized antiviral drug susceptibility assay for clinical human immunodeficiency virus type 1 (HIV-1) isolates has been developed for use in clinical trials. The protocol is a two-step procedure that first involves cocultivation of patient infected peripheral blood mononuclear cells (PBMC) with seronegative phytohemagglutinin-stimulated donor PBMC to obtain an HIV-1 stock. The virus stock is titrated for viral infectivity (50% tissue culture infective dose) by use of serial fourfold virus dilutions in donor PBMC. A standardized inoculum of 1,000 50% tissue culture infective doses per 10(6) cells is used in the second step of the procedure to acutely infect seronegative donor PBMC in a 7-day microtiter plate assay with triplicate wells containing zidovudine (ZDV) concentrations ranging from 0 to 5.0 microM. The ZDV 50% inhibitory concentrations (IC50) for reference ZDV-susceptible and ZDV-resistant HIV-1 isolates ranged from 0.002 to 0.113 microM and from 0.15 to > 5.0 microM, respectively. Use of this consensus protocol reduced interlaboratory variability for ZDV IC50 determinations with reference HIV-1 isolates. Among eight laboratories, the coefficient of variation ranged from 0.85 to 1.25 with different PBMC protocols and was reduced to 0.39 to 0.98 with the standardized assay. Among the clinical HIV-1 isolates assayed by the standardized drug susceptibility assay, the median ZDV IC50 increased gradually with more ZDV therapy. This protocol provides an efficient and reproducible means to assess the in vitro susceptibility to antiretroviral agents of virtually all clinical HIV-1 isolates.

Citing Articles

HIV-1 Tat Upregulates TREM1 Expression in Human Microglia.

Campbell G, Rawat P, To R, Spector S J Immunol. 2023; 211(3):429-442.

PMID: 37326481 PMC: 10352590. DOI: 10.4049/jimmunol.2300152.

Antiviral Activity and Resistance Profile of the Novel HIV-1 Non-Catalytic Site Integrase Inhibitor JTP-0157602.

Ohata Y, Tomonaga M, Watanabe Y, Tomura K, Kimura K, Akaki T J Virol. 2022; 96(6):e0184321.

PMID: 35045265 PMC: 8941924. DOI: 10.1128/JVI.01843-21.

CD4+ T cell-mimicking nanoparticles encapsulating DIABLO/SMAC mimetics broadly neutralize HIV-1 and selectively kill HIV-1-infected cells.

Campbell G, Zhuang J, Zhang G, Landa I, Kubiatowicz L, Dehaini D Theranostics. 2021; 11(18):9009-9021.

PMID: 34522224 PMC: 8419049. DOI: 10.7150/thno.59728.

CD4 T Cell-Mimicking Nanoparticles Broadly Neutralize HIV-1 and Suppress Viral Replication through Autophagy.

Zhang G, Campbell G, Zhang Q, Maule E, Hanna J, Gao W mBio. 2020; 11(5).

PMID: 32934078 PMC: 7492730. DOI: 10.1128/mBio.00903-20.

Trehalose Inhibits Human Immunodeficiency Virus Type 1 Infection in Primary Human Macrophages and CD4 T Lymphocytes through Two Distinct Mechanisms.

Rawat P, Hon S, Teodorof-Diedrich C, Spector S J Virol. 2020; 94(17).

PMID: 32554696 PMC: 7431788. DOI: 10.1128/JVI.00237-20.

References

Chou T, Talalay P . Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22:27-55. DOI: 10.1016/0065-2571(84)90007-4. View

Mayers D, McCutchan F, Merritt L, DILWORTH S, Fowler A, Marks C . Characterization of HIV isolates arising after prolonged zidovudine therapy. J Acquir Immune Defic Syndr (1988). 1992; 5(8):749-59. View

Larder B, Darby G, Richman D . HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989; 243(4899):1731-4. DOI: 10.1126/science.2467383. View

Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao X, Fanning M . Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS. 1989; 3(7):411-5. DOI: 10.1097/00002030-198907000-00001. View

Ho D, Moudgil T, Alam M . Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med. 1989; 321(24):1621-5. DOI: 10.1056/NEJM198912143212401. View

Coombs R, Collier A, Allain J, Nikora B, Leuther M, Gjerset G . Plasma viremia in human immunodeficiency virus infection. N Engl J Med. 1989; 321(24):1626-31. DOI: 10.1056/NEJM198912143212402. View

Burke D, Redfield R, Bjornson D, Fowler A, Oster C . Frequent isolation of HIV-1 from the blood of patients receiving zidovudine (AZT) therapy. N Engl J Med. 1989; 321(24):1682. DOI: 10.1056/NEJM198912143212414. View

Larder B, Kemp S . Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989; 246(4934):1155-8. DOI: 10.1126/science.2479983. View

Land S, Terloar G, McPhee D, Birch C, Doherty R, Cooper D . Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis. 1990; 161(2):326-9. DOI: 10.1093/infdis/161.2.326. View

10.

Larder B, Chesebro B, Richman D . Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother. 1990; 34(3):436-41. PMC: 171611. DOI: 10.1128/AAC.34.3.436. View

11.

Richman D, Grimes J, Lagakos S . Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr (1988). 1990; 3(8):743-6. View

12.

Japour A, Chatis P, Eigenrauch H, Crumpacker C . Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Proc Natl Acad Sci U S A. 1991; 88(8):3092-6. PMC: 51391. DOI: 10.1073/pnas.88.8.3092. View

13.

Nunberg J, Schleif W, Boots E, OBrien J, Quintero J, Hoffman J . Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 1991; 65(9):4887-92. PMC: 248949. DOI: 10.1128/JVI.65.9.4887-4892.1991. View

14.

Johnson V, Merrill D, Videler J, Chou T, Byington R, Eron J . Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis. 1991; 164(4):646-55. DOI: 10.1093/infdis/164.4.646. View

15.

St Clair M, Martin J, Tudor-Williams G, Bach M, Vavro C, King D . Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991; 253(5027):1557-9. DOI: 10.1126/science.1716788. View

16.

Tudor-Williams G, St Clair M, McKINNEY R, Maha M, Walter E, Santacroce S . HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet. 1992; 339(8784):15-9. DOI: 10.1016/0140-6736(92)90140-x. View

17.

Richman D, Shih C, Lowy I, Rose J, Prodanovich P, Goff S . Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A. 1991; 88(24):11241-5. PMC: 53110. DOI: 10.1073/pnas.88.24.11241. View

18.

Kellam P, Boucher C, Larder B . Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A. 1992; 89(5):1934-8. PMC: 48568. DOI: 10.1073/pnas.89.5.1934. View

19.

Jung M, Agut H, Candotti D, Ingrand D, Katlama C, Huraux J . Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis. J Acquir Immune Defic Syndr (1988). 1992; 5(4):359-64. View

20.

Eron J, Gorczyca P, Kaplan J, DAquila R . Susceptibility testing by polymerase chain reaction DNA quantitation: a method to measure drug resistance of human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A. 1992; 89(8):3241-5. PMC: 48842. DOI: 10.1073/pnas.89.8.3241. View